CARG-2020 a novel immunemodulatory approach to prevent recurrent ovarian cancer.

被引：0
|
作者：
Alvero, Ayesha B. [1 ]
Fox, Alexandra [1 ]
Madina, Bhaskara [2 ]
Krady, Marie [2 ]
Yarovinski, Timur O. [2 ]
Nakaar, Valerian [2 ]
Almassian, Bijan [2 ]
Mor, Gil [1 ]
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] Carogen, Farmington, CT USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5370
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetically monitored administration of infusional etoposide phosphate in recurrent ovarian cancer.
    Propper, DJ
    Joel, S
    Jeffrey, B
    Elliot, M
    O'Byrne, K
    Levitt, NC
    Braybrooke, JP
    Gallagher, CJ
    Slevin, ML
    Ganesan, TS
    BRITISH JOURNAL OF CANCER, 1999, 80 : 93 - 93
  • [32] The efficacy of palliative radiation therapy in the treatment of recurrent and metastatic ovarian cancer.
    Butala, Anish
    Patel, Roshal
    Jones, Joshua Adam
    Taunk, Neil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (31)
  • [33] Alternative treatment of chemoresistant, recurrent or advanced ovarian cancer. Part I
    Wilczynski, Jacek R.
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2011, 10 (03): : 181 - 186
  • [34] Cancer immunotherapy with oncolytic enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways
    Wang, Kepeng
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [35] A novel early cancer detection approach for pancreatic cancer.
    Bijlsma, Maarten F.
    Strasser, Patrick Christian
    Schneider, Maximilian Christoph
    Thumfart, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 613 - 613
  • [36] Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics
    Modesitt, Susan C.
    Jazaeri, Amir A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (14) : 2293 - 2305
  • [37] Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer.
    Kandalaft, Lana E.
    Tanyi, Janos
    Chiang, Cheryl Lai-Lai
    Torigian, Drew
    Powell, Daniel J., Jr.
    Coukos, George
    CANCER RESEARCH, 2013, 73
  • [38] Recurrent gene fusions are common in high-grade serous ovarian cancer.
    Lehtonen, Rainer
    Carpen, Olli
    Huhtinen, Kaisa
    Hynninen, Johanna
    Kaipio, Katja
    Lamminen, Tarja
    Cervera, Alejandra
    Hietanen, Sakari
    Grenman, Seija
    Hautaniemi, Sampsa
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 108 - 108
  • [39] Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer.
    Ferrandina, G.
    Ludovisi, M.
    D'Agostino, G.
    Naldini, A.
    Lorusso, D.
    Testa, A. C.
    Legge, F.
    Salutari, V.
    Scambia, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 277S - 277S
  • [40] Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer.
    Gabra, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 263S - 263S
12345